Clinical Trial Update: RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER [Phase 1]

View source ↗

Summary

The DISCOVER Phase 1 trial evaluating RTA 408 in advanced solid tumors, including metastatic non-small cell lung cancer and relapsed/refractory melanoma, has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Or Refractory Melanoma

Drugs mentioned

• RTA 408

Snippet

Sponsor: Biogen | Conditions: Metastatic or Incurable Non-small Cell Lung Cancer, Relapsed, Refractory Melanoma | Phase 1 | Status: COMPLETED